Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice

Breast Cancer Research

Volumn 13, Issue 1, 2011, Pages

  Ladjemi, Maha Z ^a   Chardes, Thierry ^a   Corgnac, Stephanie ^a   Garambois, Veronique ^a   Morisseau, Sebastien ^a   Robert, Bruno ^a   Bascoul Mollevi, Caroline ^b   Ait Arsa, Imade ^a   Jacot, William ^b   Pouget, Jean Pierre ^a   Pelegrin, Andre ^a   Navarro Teulon, Isabelle ^a  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 2; SCFV40 ANTIBODY; SCFV69 ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; SPLEEN CELL; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL STRAIN HEK293; CELL SURVIVAL; CHO CELL; HAMSTER; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NUDE MOUSE; OVARY TUMOR; TH1 CELL; TH2 CELL; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; CANCER VACCINES; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; FEMALE; HEK293 CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICE, TRANSGENIC; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; SINGLE-CHAIN ANTIBODIES; TH1 CELLS; TH2 CELLS;

EID: 84860389330     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2826     Document Type: Article

References (33)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
3. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blamey RW. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 1994, 29:117-125. 10.1007/BF00666187, 7912565.
4. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munarriz B, Rodriguez CA, Crespo C, de Alava E, Lopez Garcia-Asenjo JA, Guitian MD, Almenar S, Gonzalez-Palacios JF, Vera F, Palacios J, Ramos M, Garcia Marco JM, Lluch A, Alvarez I, Segui MA, Mayordomo JI, Anton A, Baena JM, Plazaola A, Modolell A, Pelegri A, Mel JR, Aranda E, Adrover E, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100:805-814. 10.1093/jnci/djn151, 18505968.
5. Disis ML, Schiffman K, Salazar LG, Almand B, Knutson KL. HER-2/neu vaccines. Cancer Chemother Biol Response Modif 2003, 21:275-285.
6. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994, 54:16-20.
7. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995, 92:432-436. 10.1073/pnas.92.2.432, 42754, 7831305.
8. Nanda NK, Sercarz EE. Induction of anti-self-immunity to cure cancer. Cell 1995, 82:13-17. 10.1016/0092-8674(95)90047-0, 7606778.
9. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002, 20:2624-2632. 10.1200/JCO.2002.06.171, 12039923.
10. Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides. Breast Cancer Res Treat 2005, 92:85-93. 10.1007/s10549-005-0988-1, 15980996.
11. Roth A, Rohrbach F, Weth R, Frisch B, Schuber F, Wels WS. Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct. Br J Cancer 2005, 92:1421-1429. 10.1038/sj.bjc.6602526, 2362007, 15812545.
12. Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Cancer immunoprevention. Future Oncol 2005, 1:57-66. 10.1517/14796694.1.1.57, 16555976.
13. Gritzapis AD, Mahaira LG, Perez SA, Cacoullos NT, Papamichail M, Baxevanis CN. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo. Cancer Res 2006, 66:5452-5460. 10.1158/0008-5472.CAN-05-4018, 16707474.
14. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. military cancer institute clinical trials group study I-01 and I-02. Clin Cancer Res 2008, 14:797-803. 10.1158/1078-0432.CCR-07-1448, 18245541.
15. Jerne NK. Towards a network theory of the immune system. Ann Immunol (Paris) 1974, 125C:373-389.
16. Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol 1999, 17:2889-2895.
17. Reinartz S, Kohler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Mobus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004, 10:1580-1587. 10.1158/1078-0432.CCR-03-0056, 15014007.
18. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006, 12:5503-5510. 10.1158/1078-0432.CCR-05-2670, 17000686.
19. Foon KA, Lutzky J, Baral RN, Yannelli JR, Hutchins L, Teitelbaum A, Kashala OL, Das R, Garrison J, Reisfeld RA, Bhattacharya-Chatterjee M. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000, 18:376-384.
20. De Cerio AL, Zabalegui N, Rodriguez-Calvillo M, Inoges S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 2007, 26:3594-3602. 10.1038/sj.onc.1210371, 17530013.
21. Coelho M, Gauthier P, Pugniere M, Roquet F, Pelegrin A, Navarro-Teulon I. Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br J Cancer 2004, 90:2032-2041. 10.1038/sj.bjc.6601825, 2409470, 15138490.
22. Finkle D, Quan ZR, Asghari V, Kloss J, Ghaboosi N, Mai E, Wong WL, Hollingshead P, Schwall R, Koeppen H, Erickson S. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004, 10:2499-2511. 10.1158/1078-0432.CCR-03-0448, 15073130.
23. Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. Expert Rev Anticancer Ther 2007, 7:1225-1241. 10.1586/14737140.7.9.1225, 17892423.
24. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001, 61:4892-4900.
25. Felici F, Luzzago A, Folgori A, Cortese R. Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. Gene 1993, 128:21-27. 10.1016/0378-1119(93)90148-V, 7685299.
26. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760. 10.1038/nature01392, 12610629.
27. Geysen HM, Rodda SJ, Mason TJ. A priori delineation of a peptide which mimics a discontinuous antigenic determinant. Mol Immunol 1986, 23:709-715. 10.1016/0161-5890(86)90081-7, 2432410.
28. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004, 173:394-401.
29. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu--a new method of epitope definition. Mol Immunol 2005, 42:1121-1124. 10.1016/j.molimm.2004.11.003, 15829301.
30. Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz) 2008, 56:181-191. 10.1007/s00005-008-0018-1, 18512029.
31. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, Peterson KL, Chen J, Kahn R, Condorelli G, Ross J, Chien KR, Lee KF. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002, 8:459-465. 10.1038/nm0502-459, 11984589.
32. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
33. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale?. Ann Oncol 2006, 17:750-762. 10.1093/annonc/mdj083, 16293674.